Investor Updates

Latest Financial Results

Q3 2022

Quarter Ended September 30, 2022

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

NightHawk Biosciences is a fully integrated biopharmaceutical company specializing in the end-to-end development and commercialization of therapies that arm the immune system against a wide range of diseases including cancer and infectious disease. Our ecosystem is driven by the discovery efforts of SkunkWorx Bio, Inc, the preclinical and clinical development expertise of Heat Biologics, Inc, Pelican Therapeutics, Inc, and Elusys Therapeutics, Inc., and our in-house contract research and development biomanufacturing organization (CDMO) Scorpion Biologics, Inc. These unique capabilities decrease our reliance on external vendors and reinforce our goal of increasing the efficiency of drug development to accelerate the delivery of novel immune activating therapies.

Stock Snapshot

IR Contacts


Nighthawk Biosciences, Inc.
627 Davis Drive
Suite 400
Morrisville, NC 27560
T: +1 919 240 7133

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
T: +1 212 509 4000